1. Volume 12, Issue 1, Pages 21-29 (January 2011)
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial 
Prof Jack Cuzick, PhD, Ivana Sestak, PhD, Prof Sarah E Pinder, MD, Prof Ian O Ellis, MD, Sharon Forsyth, BSc, Prof Nigel J Bundred, MD, Prof John F Forbes, MD, Hugh Bishop, MD, Prof Ian S Fentiman, MD, William D George, MD 
The Lancet Oncology 
Volume 12, Issue 1, Pages (January 2011)
DOI: /S (10)
Copyright © 2011 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
T=tamoxifen. R=radiotherapy. CT=control group for tamoxifen. CR=control group for radiotherapy.
The Lancet Oncology  , 21-29DOI: ( /S (10) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier curve for cumulative incidence and annual hazard plot of all breast events in the tamoxifen comparison
The Lancet Oncology  , 21-29DOI: ( /S (10) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

4. Figure 3
Forest plot for new breast events in the tamoxifen comparison stratified by whether or not patients received radiotherapy
HR=hazard ratio. DCIS=ductal carcinoma in situ.
The Lancet Oncology  , 21-29DOI: ( /S (10) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

5. Figure 4
Kaplan-Meier curve for cumulative incidence and annual hazard plot of all breast events in the radiotherapy comparison
The Lancet Oncology  , 21-29DOI: ( /S (10) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

6. Figure 5
Forest plot for new breast events in the radiotherapy comparison stratified by whether or not patients received tamoxifen
HR=hazard ratio. DCIS=ductal carcinoma in situ.
The Lancet Oncology  , 21-29DOI: ( /S (10) )
Copyright © 2011 Elsevier Ltd Terms and Conditions